NYSE:EWMedical Equipment
How Edwards' TAVR and TMTT Momentum Heading Into Q1 2026 (EW) Has Changed Its Investment Story
Edwards Lifesciences recently guided investor expectations ahead of its first-quarter 2026 earnings release on April 23, highlighting momentum across key structural heart therapy segments.
Market attention has centered on anticipated strength in Transcatheter Aortic Valve Replacement and the Transcatheter Mitral and Tricuspid Therapies portfolio, including the PASCAL and EVOQUE systems, as well as the premium RESILIA-based Surgical Structural Heart products.
With expectations building around...